📺 Stream EntrepreneurTV for Free 📺

Google Is Developing an Ingestible Cancer-Detecting Pill The idea is that nanoparticles will continuously monitor your body for disease triggers so they can be detected and treated as soon as they appear.

By Laura Entis

entrepreneur daily

Opinions expressed by Entrepreneur contributors are their own.

l i g h t p o e t | Shutterstock.com

Google may be best known for search and its crazy employee perks, but the company is constantly cooking up far-out, big-picture, enormously ambitious projects. Self-driving cars? Check. Face computers (i.e. Google Glass)? Double check. Contact lenses that measure glucose levels in a wearers' tears? Google's on it.

Now comes word of another moonshot project from the company's Google X division: an ingestible disease-detecting pill containing thousands of microscopic magnetic particles that course through a person's bloodstream in search of malignant cells, according to the Associated Press. If the nanoparticles find an early indication of a disease, they send out signals that can be picked up by a wearable device.

Related: Google Wants to Build a Model of Perfect Human Health

While the pill is still in its experimental stage – the company has said it could take up to 10 years for the pill to be prescribed, the AP reports – this technology has the potential to dramatically transform the way we diagnose and treat a host of diseases, most notably cancer.

Think about it. Many times, a pathogen is deadly because it goes undetected until the damage is widespread enough to cause noticeable side-effects. Early alerts that can identify malignant cells as they form have the potential to stop serious diseases in their tracks, before they have the time to wreak irreversible havoc.

Related: If You Could, Would You Want to Live Forever? Google Thinks You Might

In an interview with Medium Andrew Conrad, head of life sciences at Google X, explained why our current strategy for treating serious diseases, particularly cancer, is fundamentally backwards:

Some cancers have ninety percent success rate if you diagnose them in early stage one. But most cancers have a five or ten percent survival rate if you diagnose them in stage four. We're diagnosing cancer at the wrong time. It's analogous to only changing the oil on your car when it breaks down. If you think of airplanes or cars or any complex entity, preventative maintenance has been proven without a doubt to be the better model.

Google's pill aims to change the strategy from reactive to proactive -- adopting a "preventative maintenance" approach – by continuously monitoring the body for disease triggers, so they can be identified and treated as soon as they appear.

"Every test you ever go to the doctor for will be done through this system," Conrad said yesterday at the WSJD Live Conference. "That is our dream."

It's a beautiful one. For now, however, the project remains exactly what its name implies: a moonshot, although one that has the potential to save many, many lives.

Related: Novartis, Google to Develop Contact Lenses to Monitor Blood Sugar

Laura Entis is a reporter for Fortune.com's Venture section.

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Editor's Pick

Side Hustle

He Started a Luxury Side Hustle at Age 13 — Now the Business Earns More Than $10 Million a Year: 'People Want to Help You When You're Young'

Michael Morgan, now the owner of Iconic Watch Company, always had a passion for "old things" — and he turned it into a lucrative venture.

Thought Leaders

It's the End of the Entrepreneurial Era As We Know It

With the rise of advanced technologies and AI, are we losing all sense of the independent business person and entrepreneur?

Business Ideas

63 Small Business Ideas to Start in 2024

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2024.

Business Plans

From Camera-Shy to Camera-Ready — Here's What to Consider Before You Go on Camera

Are you ready to be on camera? Here are a few things to consider.